Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
Alzheimer’s disease (AD) is associated with metabolic abnormalities linked to critical aspects of neurodegeneration. AD involves parts of the brain that control thought, language, and memory. AD is a progressive disease that begins
Integrated Outpatient Palliative Care Versus Standard Care In Patients With Parkinson Disease And Related Disorders
Parkinson’s disease (PD) affects 1 – 2% of the population above 65 years of age and has consequences on quality of life (QoL). PD and related disorders (PDRD) tend to have additional symptoms contributing to worse prognosis